Rigel Pharmaceuticals (RIGL) Scheduled to Post Earnings on Thursday

Rigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect Rigel Pharmaceuticals to post earnings of $0.01 per share for the quarter. Investors that are interested in registering for the company's conference call can do so using this link.

Rigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.31. The firm had revenue of $36.84 million for the quarter, compared to analyst estimates of $32.38 million. During the same period in the previous year, the business posted ($0.40) earnings per share. On average, analysts expect Rigel Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Rigel Pharmaceuticals Price Performance

NASDAQ RIGL traded up $0.57 on Friday, reaching $14.20. The stock had a trading volume of 61,623 shares, compared to its average volume of 148,954. The company has a market cap of $249.78 million, a P/E ratio of -16.51 and a beta of 0.94. The firm has a fifty day moving average of $14.48 and a two-hundred day moving average of $11.63. Rigel Pharmaceuticals has a 1-year low of $7.48 and a 1-year high of $17.30.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Cantor Fitzgerald restated a "neutral" rating and issued a $15.00 price target on shares of Rigel Pharmaceuticals in a research note on Friday, September 20th. HC Wainwright restated a "buy" rating and set a $57.00 target price on shares of Rigel Pharmaceuticals in a research report on Friday, October 25th. Finally, StockNews.com raised shares of Rigel Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, October 18th. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Rigel Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $31.13.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.